'Govt Should Act Early To Buy New Covid Drug'

"); jQuery("#212 h3").html("

Related News Programmes

"); jQuery(document).ready(function() { jwplayer.key='EKOtdBrvhiKxeOU807UIF56TaHWapYjKnFiG7ipl3gw='; var playerInstance = jwplayer("jquery_jwplayer_1"); playerInstance.setup({ file: "https://newsstatic.rthk.hk/audios/mfile_1613381_1_20211004101029.mp3", skin: { url: location.href.split('/', 4).join('/') + '/jwplayer/skin/rthk/five.css', name: 'five' }, hlshtml: true, width: "100%", height: 30, wmode: 'transparent', primary: navigator.userAgent.indexOf("Trident")>-1 ? "flash" : "html5", events: { onPlay: function(event) { dcsMultiTrack('DCS.dcsuri', 'https://news.rthk.hk/rthk/en/component/k2/1613381-20211004.mp3', 'WT.ti', ' Audio at newsfeed', 'WT.cg_n', '#rthknews', 'WT.cg_s', 'Multimedia','WT.es','https://news.rthk.hk/rthk/en/component/k2/1613381-20211004.htm', 'DCS.dcsqry', '' ); } } }); }); });

2021-10-04 HKT 10:09

Share this story

facebook

  • William Chui says the new medication for Covid has the potential to save patients at risk of developing complications. File Photo: RTHK

    William Chui says the new medication for Covid has the potential to save patients at risk of developing complications. File Photo: RTHK

William Chui speaks to Wendy Wong

A pharmacists’ association said on Monday that a new drug for Covid-19 could help relieve the burden on hospitals if Hong Kong sees another outbreak of infections, adding that the government should act early to ensure the city is able to procure the medication.

The Society of Hospital Pharmacists of Hong Kong has welcomed the Hospital Authority’s plan to buy 500 courses of molnupiravir – the first oral antiviral medication for Covid-19 developed by a US drug maker.

Interim clinical trial results suggest the pills can cut the risk of hospitalisation by half.

Speaking on an RTHK programme, the society's president, William Chui, said although Hong Kong has had no local Covid cases for some time, it's a good idea for the government to approach the drug company early, as other countries are expected to compete for the new medication.

“This is a good start. I don’t think the government should wait and see because it would be too late as many countries already started to procure the new drug,” he said.

But University of Hong Kong microbiologist Ho Pak-leung said although the interim results were encouraging, trials for the drug were still incomplete.

He said the government should adopt a cautious approach and wait for more information on the drug.

Ho stressed that getting vaccinated was still the safest and most effective way to prevent complications and deaths arising from Covid-19.

RECENT NEWS

Ant International And Bank Of China Partner To Enhance Cross-Border Payment Connectivity

Ant International and Bank of China (Hong Kong) (“BOCHK”) announced a partnership which leverages BOCHK’s banking... Read more

BitGo Korea Gets Green Light For Virtual Asset Custody, Backed By SK Telecom

BitGo Holdings, Inc. (BitGo) announced that its subsidiary, BitGo Korea, Inc. (BitGo Korea), received its Virtual Asset... Read more

Webinar: When Account Takeover Moves Past Onboarding

Account takeover shows why fraud risk cannot be treated as an onboarding problem. Fraudsters are using stolen credentia... Read more

JCB To Trial Stablecoin Payments In Japan With Digital Garage And Lawson

JCB Co., Ltd. (JCB), Digital Garage, Inc. (Digital Garage), and Lawson, Inc. (Lawson) announced that they have jointly ... Read more

Bonnie Chan To Lead HKEX Until Feb 2030 After Securing Second Term

The HKEX Board of Directors has approved the renewal of the employment contract of Hong Kong Exchanges and Clearing Lim... Read more

Ripple Signs Its First Korean Regional Bank In Cross-Border Remittance Deal

Ripple, a blockchain-based enterprise solutions provider for traditional and digital finance, announced a partnership w... Read more